October 9, 2024 – Talk Bio

Astellas Expands Cell Therapy Research with New Japan Site for Universal Cells

7 months ago talkbio0Tagged allogeneic cell therapy, Astellas, Cell Therapy, Japan, Regenerative Medicine, Universal Cells

Astellas, Universal Cells, cell therapy, regenerative medicine, Japan research site, allogeneic cell therapy

Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows

7 months ago talkbio0Tagged Benchtop DNA Sequencer, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, MiSeq, Push-Button, Workflow

Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing

2024 Nobel Prize in Chemistry Awarded to Trio for Groundbreaking Protein Research

7 months ago talkbio0Tagged 2024, Baker, general, computational protein design, Demis, Hassabis, IMMUNODEFICIENCY, COMMON VARIABLE, 10, Nobel, Prediction, Prizes, Protein, Organized by Structure, Science of Chemistry

Nobel Prize in Chemistry 2024, Protein Structure Prediction, Computational Protein Design, David Baker, Demis Hassabis, John Jumper

Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges

7 months ago talkbio0Tagged Acquisition (action), Clinical Development, Pfizer, Respiratory syncytial virus, ReViral, RSV, sisunatovir, Termination - Inactive Reason Code

Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination

Pfizer CEO Albert Bourla to Engage with Activist Investor Starboard Value on Strategic Overhaul

7 months ago talkbio0Tagged activist investor, Albert, Bourla, Drug Industry, Pfizer, post-COVID, Starboard Value, Strategic Overhaul

Pfizer, Albert Bourla, Starboard Value, activist investor, pharmaceutical industry, strategic overhaul, post-COVID challenges

Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases

7 months ago talkbio0Tagged Agreement, Antibody Therapy, Aortic Valve Insufficiency, Artificial Intelligence, Drug Development, Eli, Eli Lilly, Insitro, MASLD, Metabolic, Metabolic Diseases, RNA, Small Interfering, steatotic liver disease, strategic

Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

FDA Halts Kezar’s Lupus Nephritis Trial Due to Safety Concerns Following Four Patient Deaths

7 months ago talkbio0Tagged Cessation of life, concerns, Kezar Life Sciences, Lupus Nephritis, Safety, Study on Hold, United States Food and Drug Administration, Zetomipzomib

FDA, Kezar Life Sciences, lupus nephritis, zetomipzomib, clinical hold, patient deaths, safety concerns

FDA Raises Concerns Over Stealth BioTherapeutics’ Ultra-Rare Disease Drug Ahead of Advisory Committee Meeting

7 months ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Advisory Committees, concerns, Drug Approval, Effectiveness, Elamipretide, Stealth BioTherapeutics, ultra-rare disease, United States Food and Drug Administration

FDA, Stealth BioTherapeutics, elamipretide, Barth syndrome, ultra-rare disease, advisory committee meeting, drug approval, efficacy concerns

Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy

7 months ago talkbio0Tagged Biogen, Clinical Trials, DEVOTE, Dose Regimen, High, Improvement, Motor function (observable entity), Nerve Degeneration, nusinersen, Spinal Muscular Atrophy, Spinraza

Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction

Zealand’s Hypoglycemia Drug Faces Second FDA Rejection Due to Manufacturing Issues

7 months ago talkbio0Tagged CDMO, Congenital MeSH qualifier, dasiglucagon, Hyperinsulinism, Hypoglycemia, Inspection (procedure), Rejection (Psychology), United States Food and Drug Administration, Zealand Pharma

Zealand Pharma, FDA rejection, dasiglucagon, congenital hyperinsulinism, hypoglycemia, CDMO inspection